Rapid modulation of acetylcholine receptor synthesis  by Pezzementi, Leo & Schmidt, Jakob
Volume 135, number 1 FEBS LETTERS November 1981 
RAPID MODULATION OF ACETYLCHOLINE RECEPTOR SYNTHESIS 
Leo PEZZEMENTI and Jakob SCHMIDT 
Department of Biochemistry, State University of New York, Stony Brook, NY 11794, USA 
Received 7October 1981 
1. Introduction 
Electrical stimu.lation of adult denervated muscle 
leads to inhibition of acetylcholine r ceptor synthesis 
[ 1,2]. How information about the activity of the 
sarcolemma is conveyed to the protein-synthesizing 
apparatus i largely unknown. Some progress has been 
made with the use of myogenic ells in culture, which 
resemble denervated muscle fibers and respond to 
specific drug treatments with characteristic changes in 
receptor synthesis rate. For instance, pharmacological 
blockage [3], or activation [4], of sodium channels, 
result in acceleration or slow-down, respectively, of
acetylcholine r ceptor synthesis. Dantrolene, which 
blocks release of Ca 2÷ from the sarcoplasmic reticu- 
lum (SR), stimulates receptor synthesis [5], while 
ryanodine, when used at the low concentration at
which it is thought o deplete calcium from the SR, 
has the opposite ffect (L. P., J. S., unpublished). The 
notion that calcium may play a messenger role in 
acetylcholine r ceptor regulation is supported by sev- 
eral other experiments [6,7]. 
Subsequent s eps in the signaling pathway are not 
known. We have studied the effect of various drugs 
on receptor synthesis in chick myotubes at high tem- 
poral resolution, to determine if receptor synthesis i
shut off at the transcriptional or post-transcriptional 
level. The findings suggest that pharmacological 
agents capable of turning off receptor synthesis act 
on the protein synthesizing apparatus rather than on 
the genome. 
2. Experimental 
2.1. Cell culture 
Muscle cells for primary cultures were obtained 
from the legs of 12-day-old SPAFAS (Norwich CT) 
chick embryos by mechanical disruption as in [8]. 
Routinely, cells were plated at 5 × 10s/35 mm gela- 
tin-coated, tissue culture dish (Falcon). The cells were 
cultured in 88% Dulbecco's modified Eagle's medium 
(DME; GIBCO, Grand Island NY), 10% horse serum 
(GIBCO), and 2% embryo extract at 37°C, in a 95% 
air-5% COz water-saturated atmosphere. Cells were 
treated with 10 -s M cytosine arabinoside from 
48-96 h in culture to suppress proliferation of 
fibroblasts. 
2.2. Acetylcholine receptor synthesis rate assay 
Pre-existing cell surface receptors were blocked by 
incubation for 40 min in 10 -7 M a-bungarotoxin 
(aButx) added to the medium. Cells were then freed 
of unbound aButx by 4 1-min washes with Hank's 
balanced salt solution containing 1mg BSA/ml. The 
cultures were divided into two groups. Those to be 
assayed for receptor synthesis rate were fed with 
DME and incubated for another hour at 37°C. Drugs 
were included in the media for the desired period 
(before, during, and after treatment with aButx) such 
that the last hour of drug exposure coincided with 
the DME incubation. Afterwards, the cultures were 
washed twice for 1 min with 280 mM mannitol, 
10 mM Hepes (pH 7.4) and incubated with 10 -9 M 
x2sI-aButx for 30 rain. The low ionic strength man- 
nitol solution was based to reduce the time required 
for saturation of toxin-binding sites. Incubations were 
terminated by a l-rain wash with phosphate-buffered 
saline (PBS) containing 1mg BSA/ml, followed by 3 
1-min washes with PBS. Cultures were then solubil- 
ized in 0.1 N NaOH, 0.1% SDS and counted in a 
7-counter. Cultures to be used as controls for back- 
ground binding activity were incubated with 10 ~9 M 
12sI-aButx in 280 mM mannitol, 10 mM Hepes 
(pH 7.4) immediately after washing out aButx. This 
binding activity (~60% of total) represents receptor 
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not blocked by aButx during preincubation (due to 
protection by cations in the high-ionic strength 
medium); receptor inserted into the membrane during 
incubation with 12sI-aButx; and non-specific binding 
as defined by binding of lZSI-aButx in the presence of 
10 -s M decamethonium. Non-specific binding was 
not routinely measured, as it ~vas found to be identi- 
cal for receptor appearance rate and control cultures. 
The difference between experimental nd control 
values is considered as the amount of receptor appear- 
ing on the surface membrane per hour and culture. 
Saturation studies howed that the binding reaction 
went to 90% completion i  <30 min incubation with 
10 -9 M mono-lZSI-aButx. In some experiments 
di-12sI-aButx was used. In this case incubation was 
for 45 min. 
2.3. R eagen ts 
MonoJ2SI-c~Butx and diJ2sI-aButx at spec. act. 
~2.5 × l0 7 and 4.0 × 10 7 GBq/mol, respectively, 
were prepared as in [9]. Ryanodine was purchased 
from Penick (Lyndhurst NJ). Puromycin, actinomy- 
cin D, tetrodotoxin and veratridine were obtained 
from Sigma. 
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Fig.1. Acetylcholine r ceptor appearance rate as a function 
of culture age. Myogenic ells were prepared and cultured, 
and hourly receptor appearance rates measured atthe indi- 
cated times after plating, as in section 2. Different symbols 
refer to separate experiments. 
3. Results and discussion 
Use of a receptor appearance rate assay of high 
temporal resolution minimizes distortion caused by 
receptor turnover (~47%/day; 2.6%/hour in our cul- 
tures). Fig.1 shows receptor appearance rate as a 
function of culture age. Receptor production peaks at 
the time of myoblast fusion, and then gradually 
declines to ~5 fmol/h and culture. Little change in 
synthesis rate is seen after day 5, the age used for 
these pharmacological experiments. 
The pathway linking membrane activity and acetyl- 
choline receptor regulation differs from other signal- 
ing pathways in muscle (e.g., excitation-contraction 
coupling (ECC) or regulation of glucose mobilization) 
in that it affects macromolecular synthesis. To obtain 
more information on its distal limb we have com- 
pared drugs that specifically affect acetylcholine 
receptor synthesis with general RNA and protein syn- 
thesis inhibitors. Reduction of receptor synthesis rate 
was observed as early as 1 h after addition of the pro- 
tein synthesis blocker puromycin (fig.2). A reduction 
to half the initial value was seen after ~3 h, the aver- 
age time required for newly made membrane proteins 
in myogenic ells to traverse the rough endoplasmic 
reticulum (RER) and Golgi apparatus and emerge on 
the cell surface [10]. After ~6 h cells began to dete- 
riorate rapidly and by 8 h receptor proliferation 
ceased. The gradual course of the puromycin effect 
probably arises from a range of transport times. 
The specific inhibitory effect of electrical stimula- 
tion on receptor synthesis can be mimicked with 
compounds that activate sodium channels uch as 
veratridine [4], or with ryanodine, a drug that shifts 
Ca 2+ from the SR to the cytosol [11 ]. As seen in 
fig.3, both drugs bring about a rapid inhibition of 
receptor proliferation. The latency periods are some- 
what longer which may be related to their action on 
the protein synthesis machinery being less direct than 
that of puromycin. With ryanodine, a fairly rapid par- 
tial recovery is seen, and veratridine never produces 
more than partial inhibition. Perhaps this indicates 
that compensatory activities are triggered. 
About 8 h after actinomycin D, at a close suffi- 
cient to terminate RNA synthesis, is applied to the 
cultures, agradual decline of the health and viability 
(as judged morphologically) of the myotubes, and 
concomitant reduction in receptor appearance rate 
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Fig.2.  Effect of  puromycin and actinomycin D on receptor 
appearance rate, Receptor appearance rates were measured, 
as in section 2, after exposure to 4 × 10 -s M puromyc in  (o) 
or 8 X 10 -4 M act inomyc in  D (o) for the indicated periods. 
Data  from several independent experiments are presented as 
fractions of  drug-free controls _+ SE. Water:ethylene glycol 
(1:1)  was used as a solubilizer for actinomycin D. Control 
experiments howed that ethylene glycol has no effect on 
receptor appearance rate at the final concentration used 
(0.5% v/v). 
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Fig.3.  Effect of veratridine and ryanod ine .  Receptor appear- 
ance rates were measured as in section 2 after exposure to 
3.0 X 10 -6 M verat r id ine  (o) and  3.0 X 10 -7 M ryanod ine  (o) 
for the indicated periods. Ryanodine was made up fresh at 
3 X 10 -5 M in ttank's balanced salt solution, 10 mM Hepes 
(pH 7.4) ,  1 mg BSA/ml .  Results are expressed as fraction of  
drug free controls +_ SE. 
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Fig,4. Effect of  tetrodotoxin, Receptor appearance rates 
upon exposure to 1.0 × 10 -6 M te t rodotox in  for the indi- 
cated  periods were measured as described and results are 
presented as in f ig.2. 
are observed (fig.2). Appearance rate is reduced to 
50% of control values between 8 -16  h incubation, i.e., 
over 8 h. This represents a lower limit of tile half-life 
of receptor-specific message. 
Another estimate of this message half-life can be 
derived from the tetrodotoxin experiment (fig.4). Here, 
as above, receptor synthesis rate is assumed to reflect 
the level of  translatable receptor message. Tetrodo- 
toxin causes an increase in receptor synthesis rate 
which probably involves a stimulation of receptor 
message synthesis, as is suggested by the actinomy- 
cin D sensitivity of this effect [6]. Thus the drug 
switches myotubes from a state, characterized by a 
specific amount of receptor specific mRNA, to a new 
state in which the level of mRNA is elevated, and the 
half-life of receptor mRNA is revealed by the time 
constant with which the new steady state is being 
approached [12]. Both the actinomycin D and tetro- 
dotoxin experiments indicate that receptor mRNA is 
fairly stable (minimal half-lives of ~10 h and 20 h, 
respectively). 
There have been several attempts to measure the 
kinetics of the reduction of receptor synthesis; results 
have been difficult to interpret because of variability 
and insufficient emporal resolution of the measure- 
ments (review [13]). This work clearly shows that 
termination of receptor synthesis upon treatmefit of 
myotubes with activators of sodium channels and SR 
is faster than would be expected from cessation of 
receptor mRNA synthesis and is thus mediated by 
some post-transcriptional event. 
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